209 related articles for article (PubMed ID: 33799005)
1. The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancer.
Rizzo A
Cancer Treat Res Commun; 2021; 27():100360. PubMed ID: 33799005
[No Abstract] [Full Text] [Related]
2. Pursuing efficacious systemic therapy for hepatocellular carcinoma.
Cheng AL
Nat Rev Gastroenterol Hepatol; 2021 Feb; 18(2):95-96. PubMed ID: 33408363
[No Abstract] [Full Text] [Related]
3. Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers.
Harris WP; Wong KM; Saha S; Dika IE; Abou-Alfa GK
Semin Oncol; 2018 Jun; 45(3):116-123. PubMed ID: 30348531
[TBL] [Abstract][Full Text] [Related]
4. Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy.
Rizzo A; Ricci AD; Brandi G
Future Oncol; 2021 Mar; 17(7):755-757. PubMed ID: 33508960
[No Abstract] [Full Text] [Related]
5. New systemic agents for hepatocellular carcinoma: an update 2020.
von Felden J
Curr Opin Gastroenterol; 2020 May; 36(3):177-183. PubMed ID: 32101985
[TBL] [Abstract][Full Text] [Related]
6. Systemic and targeted therapy for biliary tract tumors and primary liver tumors.
Thomas MB
Surg Oncol Clin N Am; 2014 Apr; 23(2):369-81. PubMed ID: 24560115
[TBL] [Abstract][Full Text] [Related]
7. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
Yau T; Pang R; Chan P; Poon RT
Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
[TBL] [Abstract][Full Text] [Related]
8. Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.
DeLeon TT; Ahn DH; Bogenberger JM; Anastasiadis PZ; Arora M; Ramanathan RK; Aqel BA; Vasmatzis G; Truty MJ; Oklu R; Bekaii-Saab TS; Borad MJ
Future Oncol; 2018 Mar; 14(6):553-566. PubMed ID: 29460642
[TBL] [Abstract][Full Text] [Related]
9. Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma.
Sharma R; Motedayen Aval L
Front Immunol; 2021; 12():652007. PubMed ID: 33790915
[TBL] [Abstract][Full Text] [Related]
10. The evolving treatment landscape of advanced urothelial carcinoma.
Andreev-Drakhlin AY; Egoryan G; Shah AY; Msaouel P; Alhalabi O; Gao J
Curr Opin Oncol; 2021 May; 33(3):221-230. PubMed ID: 33818541
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma.
Wang Y; Jiang M; Zhu J; Qu J; Qin K; Zhao D; Wang L; Dong L; Zhang X
Biomed Pharmacother; 2020 Dec; 132():110797. PubMed ID: 33068935
[TBL] [Abstract][Full Text] [Related]
12. The role of sorafenib in hepatocellular carcinoma.
Gholam P
Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581
[No Abstract] [Full Text] [Related]
13. Evolution of Systemic Therapy for Hepatocellular Carcinoma.
Finn RS; Zhu AX
Hepatology; 2021 Jan; 73 Suppl 1():150-157. PubMed ID: 32380571
[TBL] [Abstract][Full Text] [Related]
14. Immuno-oncology for Hepatocellular Carcinoma: The Present and the Future.
Armstrong SA; He AR
Clin Liver Dis; 2020 Nov; 24(4):739-753. PubMed ID: 33012456
[TBL] [Abstract][Full Text] [Related]
15. Is there any place for novel agents in treating biliary tract cancer?
Perego G; Burgio V; Nozza R; Longobardo G; Bernecich M; Luciani A; Petrelli F
Med Oncol; 2021 Feb; 38(2):19. PubMed ID: 33543377
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation.
Zhuang L; Mou HB; Yu LF; Zhu HK; Yang Z; Liao Q; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Feb; 19(1):91-93. PubMed ID: 31706859
[No Abstract] [Full Text] [Related]
17. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial.
Mei K; Qin S; Chen Z; Liu Y; Wang L; Zou J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741732
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis?
Chen WC; Chen W; Tseng GC; Lai HC; Shih CM; Hsia TC
Liver Int; 2010 Nov; 30(10):1548-9. PubMed ID: 20345702
[No Abstract] [Full Text] [Related]
19. Shadows in the current management of hepatocellular carcinoma in Spain - An embarrassing truth.
Crespo J; Andrade RJ
Rev Esp Enferm Dig; 2019 Oct; 111(10):727-730. PubMed ID: 31566408
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib in advanced hepatocellular carcinoma.
Palmer DH
N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065750
[No Abstract] [Full Text] [Related]
[Next] [New Search]
